FDA approves Novo Nordisk's Rivfloza therapy for rare kidney condition
Novo Nordisk gained access to treatment through its acquisition of Dicerna Pharmaceuticals for $3.3B
Rep. Buddy Carter: 'Pharmaceutical independence is important to national security'
Rep. Buddy Carter, R-Ga., discusses the 'Made in America Act,' decoupling from China and Bill Gates' meeting Chinese President Xi Jinping.
Novo Nordisk said on Monday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a rare genetic condition that affects the kidneys.
The once-monthly injection, which will be sold under the brand name Rivfloza, is approved for use in children who are 9 years of age and older and adults with a type of primary hyperoxaluria and relatively preserved kidney function.
A general view of the headquarters of Danish pharmaceutical company Novo Nordisk in Copenhagen, Denmark, on Sept. 26, 2023. (REUTERS/Tom Little/File photo / Reuters Photos)
CLICK HERE TO GET THE FOX NEWS APP
Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones.
The Danish drugmaker gained access to the therapy through its $3.3 billion buyout of Dicerna Pharmaceuticals.